 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12 |
- ||||||| berdazimer sodium (SB204) / Sato Pharma, Novan
Trial completion, Trial primary completion date: P3 Study in Acne Comparing Once Daily SB204 and Vehicle (clinicaltrials.gov) - Dec 18, 2017
P3, N=1306, Completed, Sponsor: Novan, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Dec 2016 | Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Dec 2016 | Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Dec 2016
- ||||||| berdazimer sodium (SB204) / Sato Pharma, Novan
Trial completion, Trial primary completion date: P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne (clinicaltrials.gov) - Dec 18, 2017
P3, N=1300, Completed, Sponsor: Novan, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Dec 2016 | Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Dec 2016 | Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Dec 2016 | Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Dec 2016 | Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Dec 2016
- berdazimer sodium (SB204) / Sato Pharma, Novan
Clinical: Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris (clinicaltrials.gov) - Jan 4, 2017
P1, N=18, Active, not recruiting, Sponsor: Novan, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Dec 2016 | Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Dec 2016 | Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Dec 2016 Trial primary completion date: Dec 2016 --> Jun 2017
- ||| SB208 / Novan
Clinical: SB208 for the Treatment of Tinea Pedis (clinicaltrials.gov) - Jan 4, 2017
P2, N=222, Active, not recruiting, Sponsor: Novan, Inc.
Trial primary completion date: Dec 2016 --> Jun 2017 Recruiting --> Active, not recruiting | N=170 --> 222
- ||||| berdazimer sodium (SB204) / Sato Pharma, Novan
Clinical: P3 Study in Acne Comparing Once Daily SB204 and Vehicle (clinicaltrials.gov) - Dec 22, 2016
P3, N=1306, Active, not recruiting, Sponsor: Novan, Inc.
Recruiting --> Active, not recruiting | N=170 --> 222 Recruiting --> Active, not recruiting
- ||||| berdazimer sodium (SB204) / Sato Pharma, Novan
Clinical: P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne (clinicaltrials.gov) - Dec 22, 2016
P3, N=1300, Active, not recruiting, Sponsor: Novan, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| SB208 / Novan
New P2 trial: SB208 for the Treatment of Tinea Pedis (clinicaltrials.gov) - Aug 9, 2016
P2, N=170, Recruiting, Sponsor: Novan, Inc.
- ||| berdazimer sodium (SB206) / Novan, Sato Pharma
Clinical: Topical NVN1000 for the Treatment of External Genital and Perianal Warts (clinicaltrials.gov) - Aug 3, 2016
P2, N=108, Active, not recruiting, Sponsor: Novan, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- berdazimer sodium (SB204) / Sato Pharma, Novan
Clinical: Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris (clinicaltrials.gov) - Aug 3, 2016
P1, N=18, Active, not recruiting, Sponsor: Novan, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| berdazimer sodium (SB204) / Sato Pharma, Novan
Clinical: P3 Long Term Safety Study of Once Daily SB204 in Acne (clinicaltrials.gov) - Aug 3, 2016
P3, N=605, Active, not recruiting, Sponsor: Novan, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | berdazimer sodium (SB204) / Sato Pharma, Novan
New P1 trial: Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris (clinicaltrials.gov) - Jun 16, 2016
P1, N=18, Recruiting, Sponsor: Novan, Inc.
- |||||||||| berdazimer sodium (SB204) / Sato Pharma, Novan
New P3 trial: P3 Long Term Safety Study of Once Daily SB204 in Acne (clinicaltrials.gov) - Jun 15, 2016
P3, N=600, Recruiting, Sponsor: Novan, Inc.
- || berdazimer sodium (SB206) / Novan, Sato Pharma
Clinical: Topical NVN1000 for the Treatment of External Genital and Perianal Warts (clinicaltrials.gov) - Jun 13, 2016
P2, N=120, Recruiting, Sponsor: Novan, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: May 2016 --> Dec 2016
- ||| berdazimer sodium (SB204) / Sato Pharma, Novan
Trial completion: A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204 (clinicaltrials.gov) - Jun 13, 2016
P1, N=56, Completed, Sponsor: Novan, Inc.
Trial primary completion date: May 2016 --> Dec 2016 Active, not recruiting --> Completed
- |||||| berdazimer sodium (SB204) / Sato Pharma, Novan
Clinical: P3 Study in Acne Comparing Once Daily SB204 and Vehicle (clinicaltrials.gov) - Mar 3, 2016
P3, N=1300, Recruiting, Sponsor: Novan, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||| berdazimer sodium (SB204) / Sato Pharma, Novan
Clinical: P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne (clinicaltrials.gov) - Feb 27, 2016
P3, N=1300, Recruiting, Sponsor: Novan, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| berdazimer sodium (SB204) / Sato Pharma, Novan
New P3 trial: P3 Study in Acne Comparing Once Daily SB204 and Vehicle (clinicaltrials.gov) - Feb 3, 2016
P3, N=1300, Not yet recruiting, Sponsor: Novan, Inc.
- |||||||||| berdazimer sodium (SB204) / Sato Pharma, Novan
New P3 trial: P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne (clinicaltrials.gov) - Jan 29, 2016
P3, N=1300, Not yet recruiting, Sponsor: Novan, Inc.
- || berdazimer sodium (SB204) / Sato Pharma, Novan
Enrollment closed: A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204 (clinicaltrials.gov) - Jan 27, 2016
P1, N=56, Active, not recruiting, Sponsor: Novan, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| berdazimer sodium (SB204) / Sato Pharma, Novan
New P1 trial: A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204 (clinicaltrials.gov) - Oct 22, 2015
P1, N=56, Recruiting, Sponsor: Novan, Inc.
- |||| berdazimer sodium (SB204) / Sato Pharma, Novan
Trial completion: P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris (clinicaltrials.gov) - Aug 20, 2015
P2, N=200, Completed, Sponsor: Novan, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| berdazimer sodium (SB206) / Novan, Sato Pharma
Clinical: Topical NVN1000 for the Treatment of External Genital and Perianal Warts (clinicaltrials.gov) - Jun 3, 2015
P2, N=120, Recruiting, Sponsor: Novan, Inc.
- | berdazimer sodium (SB204) / Sato Pharma, Novan
Trial completion: A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris (clinicaltrials.gov) - Apr 3, 2015
P1, N=18, Completed, Sponsor: Novan, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| berdazimer sodium (SB204) / Sato Pharma, Novan
Enrollment closed: P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris (clinicaltrials.gov) - Mar 31, 2015
P2, N=200, Active, not recruiting, Sponsor: Novan, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| berdazimer sodium (SB204) / Sato Pharma, Novan
Enrollment open: P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris (clinicaltrials.gov) - Nov 6, 2014
P2, N=200, Recruiting, Sponsor: Novan, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- berdazimer sodium (SB204) / Sato Pharma, Novan
New P1 trial: A Phase 1 Study Assessing Local Cutaneous Effects of SB204 (clinicaltrials.gov) - Sep 28, 2014
P1, N=8, Completed, Sponsor: Novan, Inc.
- ||||| berdazimer sodium (SB204) / Sato Pharma, Novan
New P2 trial: P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris (clinicaltrials.gov) - Sep 19, 2014
P2, N=200, Not yet recruiting, Sponsor: Novan, Inc.
- | berdazimer sodium (SB204) / Sato Pharma, Novan
New P1 trial: A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris (clinicaltrials.gov) - Jun 18, 2014
P1, N=18, Active, not recruiting, Sponsor: Novan, Inc.
- |||| berdazimer sodium (SB204) / Sato Pharma, Novan
Trial completion: A Phase 2, 3 Arm Study of NVN1000 Gel and Vehicle Gel in Subjects With Acne (clinicaltrials.gov) - Jan 9, 2014
P2, N=153, Completed, Sponsor: Novan, Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed
- | berdazimer sodium (SB204) / Sato Pharma, Novan
Trial completion: A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel (clinicaltrials.gov) - Jan 9, 2014
P1, N=30, Completed, Sponsor: Novan, Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- | berdazimer sodium (SB204) / Sato Pharma, Novan
Trial completion: A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers (clinicaltrials.gov) - Jan 9, 2014
P1, N=15, Completed, Sponsor: Novan, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| berdazimer sodium (SB204) / Sato Pharma, Novan
Trial completion: Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers (clinicaltrials.gov) - Jan 9, 2014
P1, N=60, Completed, Sponsor: Novan, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| berdazimer sodium (SB204) / Sato Pharma, Novan
New P2 trial: A Phase 2, 3 Arm Study of NVN1000 Gel and Vehicle Gel in Subjects With Acne (clinicaltrials.gov) - Apr 29, 2013
P2, N=153, Completed, Sponsor: Novan, Inc.
- | berdazimer sodium (SB204) / Sato Pharma, Novan
New P1 trial: A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel (clinicaltrials.gov) - Apr 29, 2013
P1, N=30, Completed, Sponsor: Novan, Inc.
- | berdazimer sodium (SB204) / Sato Pharma, Novan
New P1 trial: A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers (clinicaltrials.gov) - Dec 20, 2012
P1, N=15, Completed, Sponsor: Novan, Inc.
- ||| berdazimer sodium (SB204) / Sato Pharma, Novan
New P1 trial: Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers (clinicaltrials.gov) - Sep 25, 2012
P1, N=60, Completed, Sponsor: Novan, Inc.
- berdazimer sodium (SB204) / Sato Pharma, Novan
Clinical: Study of NVN1000 Topical Gel and Topical Gel Vehicle in the Treatment of Moderate to Severe Acne Vulgaris (clinicaltrials.gov) - Mar 13, 2012
P1/2, N=0, Completed, Sponsor: Novan, Inc.